Introduction
The aim of the clinical guideline published by the National Osteoporosis Foundation of South Africa (NOFSA) is to improve the overall efficacy of the diagnosis and management of patients with, or at risk of, osteoporosis. 1 Major considerations in the development of the guideline include the prevention of osteoporotic fractures and reduction in morbidity and mortality. 1 Although no accurate fracture data exist in South Africa, the incidence of osteoporosis in white, Asian and mixedrace populations appears to be similar to that in developed countries. While osteoporosis of the hip is less prevalent in the black population, vertebral bone mass and vertebral fracture prevalence appear to be similar in black and white South Africans. 1 As such, a key recommendation of the guideline is to improve awareness about osteoporosis, its prevention, treatment and complications, and to help facilitate broader access to health care for all patients with osteoporosis. 1 To describe the quality of evidence and the strength of recommendation, the guideline made use of the Grading of Recommendation, Assessment and Development and Evaluation (GRADE) criteria. GRADE uses four categories of quality: high (ØØØØ), where further research is unlikely to change the confidence in the estimate of effect; moderate (ØØØO), where research is likely to have an important impact on the confidence in the estimate of effect and may change the estimate; low (ØØOO), where research is very likely to change the estimate; and very low (ØOOO), where any estimate of effect is unclear.
What is osteoporosis?
The World Health Organization (WHO) has defined osteoporosis as "a systemic skeletal disease characterised by low bone mass and microarchitectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fracture, which usually involves the wrist, spine, hip, ribs, pelvis or humerus". 2 
Diagnosis of osteoporosis
Osteoporosis diagnosis is based on the measurement of bone mineral content, or bone mineral density (BMD), which is a surrogate marker of bone strength and fracture risk. The diagnosis may also be made clinically on the basis of a history or evidence of a fragility fracture. Several clinical risk factors have been identified and although they lack sensitivity and differ among patient populations, they impact on one other and are additive in predicting fracture. 1 NOFSA recommends that clinical risk factors should always be included in the assessment of fracture risk (Table I ).
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Managing osteoporosis: the NOFSA integrated approach
It is important to emphasise that intervention thresholds are not always the same as diagnostic criteria. In osteoporosis, the diagnostic criteria are firmly established, while the intervention threshold as to when to start specific treatment or prophylaxis remains controversial, especially if the need to intervene is not apparent after BMD and clinical risk factor assessment. 1 NOFSA recommends an integrated approach to managing osteoporosis in postmenopausal women and men over the age of 50 years: 1 • Consider treatment when a prior fragility fracture is present, regardless of the results of the BMD assessment (ØØØO).
• Consider treatment in patients with established osteoporosis (decision based upon a BMD T-score of ≤ -2.5 measured at the hip or spine) (ØØØO).
• Consider treatment in patients with osteopenia (decision based upon an assessment of the BMD and clinical risk factors) (ØØOO). Age over 75 years is generally agreed upon as an intervention threshold, as is the presence of two or more major clinical risk factors in patients ≥ 65 years of age.
Note: Treatment should always be individualised and algorithmic recommendations should never replace good clinical judgment.
Non-pharmacological management of osteoporosis
Non-pharmacological measures to improve bone strength include a healthy eating plan, physical exercise, limiting alcohol consumption, stopping smoking and avoiding the use of bone-toxic medicines.
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• A healthy eating plan, containing the correct amount of energy and all essential nutrients (including calcium 1 000-1 200 mg/day and vitamin D 800-1 000 IU/day), with adequate but not excessive protein, is recommended (ØØØO). 1 Calcium is important for the attainment of peak BMD in children. 6 Calcium deficiency has a more pronounced effect on age-related bone loss, and intervention later in life appears to be more beneficial.
• Physical exercise is important for normal bone formation. Regular exercise (e.g. walking 5 km per day at a brisk pace, four days a week) has been shown to improve BMD in postmenopausal women. 7 Excessive exercise (e.g. marathon runners and ballet dancers), coupled with caloric restriction and a poor calcium intake, may result in functional hypogonadism (e.g. amenorrhoea) and osteoporosis.
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• The effect of alcohol on bone strength appears to be dose-related and intakes of three or more units of alcohol per day are associated with a higher risk for osteoporosis. 1 One unit of alcohol contains about 10 g of ethanol (e.g. 25 ml spirits/liqueur, 125 ml wine, 340 ml beer or 60 ml sherry).
• Smoking is an independent risk factor for osteoporosis. It is also associated with early menopause and lower body weight. Smoking lowers the intestinal absorption of calcium and is often associated with alcohol use and a sedentary lifestyle. 1 • A number of medicines predispose to fracture, either by reducing bone strength and/or by predisposing to a fall (Table II) . • Stimulators of bone formation (e.g. teriparatide).
• Dual-acting agents (e.g. strontium ranelate).
NOFSA recommendations on the use of antiresorptive agents 1
• Consider calcium supplementation if adequate calcium intake cannot be obtained from the diet. The elemental calcium content varies with the calcium supplement used. A calcium supplement that provides 500 mg of elemental calcium is usually sufficient to increase the calcium intake to the recommended levels (see Table   III ). Supplements containing calcium carbonate are best taken with meals, as the absorption is improved in the presence of gastric acid.
• The prophylactic dose of vitamin D is 800 to 1 000 IU/day.
If serum 25-hydroxyvitamin D levels suggest vitamin D deficiency, higher doses may be required, e.g. 50 000 IU every two weeks (ØØØO).
• Hormone therapy with oestrogen (and progestogen in women with an intact uterus) may be considered for the treatment of menopausal women at risk of osteoporotic fracture who also present with vasomotor symptoms or urogenital atrophy, and who are in the 50-60 year age group (ØØØO). Consider a transdermal preparation in women with metabolic syndrome (i.e. obese, glucose intolerant, dyslipidaemia or hypertensive), those with hypertriglyceridaemia, and in smokers.
• Selective oestrogen receptor modulators (SERMs), such as raloxifene, may be considered for women requiring predominantly vertebral fracture protection and who are also at risk of breast cancer (ØØØO).
• Bisphosphonates, such as alendronate, are considered NOFSA recommendation on the use of strontium ranelate 1 Preclinical studies suggest that strontium ranelate has a dual mode of action, stimulating bone formation and inhibiting bone resorption. Strontium ranelate should be regarded as first-line therapy for postmenopausal osteoporosis. It is effective in those with osteoporosis and in those with osteopenia, including patients > 80 years of age (ØØØO). Strontium ranelate should be taken on an empty stomach. It is best avoided in patients with a history of venous thromboembolism and should be discontinued if a skin rash develops within two to three months of initiating treatment.
NOFSA recommendation on the choice of pharmacological agent 1 There are few studies that have compared the relative efficacy and safety of medicines used in the management of postmenopausal osteoporosis. Therefore, the choice of pharmacological therapy depends on the disease profile, the patient profile and available resources (Table IV) . 1 Men, young premenopausal women and children are best referred to a specialist centre for evaluation and treatment.
